AWM Investment Company Inc. Takes $4.88 Million Position in Xtant Medical Holdings, Inc. $XTNT

AWM Investment Company Inc. purchased a new stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,596,621 shares of the medical device company’s stock, valued at approximately $4,875,000. AWM Investment Company Inc. owned 5.06% of Xtant Medical as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of XTNT. Jane Street Group LLC purchased a new stake in Xtant Medical during the 2nd quarter valued at about $26,000. Crescent Grove Advisors LLC lifted its position in Xtant Medical by 94.3% in the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock valued at $304,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Nantahala Capital Management LLC increased its stake in shares of Xtant Medical by 500.3% in the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after buying an additional 57,000,000 shares during the period. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Xtant Medical Stock Performance

Shares of Xtant Medical stock opened at $0.73 on Friday. Xtant Medical Holdings, Inc. has a 12 month low of $0.33 and a 12 month high of $0.95. The firm has a market capitalization of $101.50 million, a P/E ratio of 72.57 and a beta of -0.05. The company has a current ratio of 2.21, a quick ratio of 1.06 and a debt-to-equity ratio of 0.35. The business has a fifty day simple moving average of $0.72 and a two-hundred day simple moving average of $0.67.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its quarterly earnings results on Monday, November 10th. The medical device company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. The firm had revenue of $27.77 million for the quarter, compared to analysts’ expectations of $32.70 million. Xtant Medical had a return on equity of 3.77% and a net margin of 1.32%.

Wall Street Analyst Weigh In

Separately, BTIG Research cut their price target on shares of Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Xtant Medical currently has an average rating of “Buy” and an average price target of $1.50.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.